VERICI DX PLC LS-001
Verici Dx plc, together with its subsidiary, Verici Dx Inc, develops prognostic and diagnostic tests for kidney transplant patients in the United Kingdom and the United States. The company develops Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; and Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failur… Read more
Market Cap & Net Worth: VERICI DX PLC LS-001 (63V)
VERICI DX PLC LS-001 (F:63V) has a market capitalization of $6.21 Million (€6.05 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #36826 globally and #4598 in its home market, demonstrating a -20.00% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying VERICI DX PLC LS-001's stock price €0.00 by its total outstanding shares 1513394127 (1.51 Billion).
VERICI DX PLC LS-001 Market Cap History: 2020 to 2026
VERICI DX PLC LS-001's market capitalization history from 2020 to 2026. Data shows change from $1.04 Billion to $6.21 Million (-59.87% CAGR).
VERICI DX PLC LS-001 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how VERICI DX PLC LS-001's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 63V by Market Capitalization
Companies near VERICI DX PLC LS-001 in the global market cap rankings as of March 19, 2026.
Key companies related to VERICI DX PLC LS-001 by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #90 globally with a market cap of $177.20 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #151 globally with a market cap of $122.79 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #466 globally with a market cap of $46.38 Billion USD.
- Lonza Group Ltd (PINK:LZAGF): Ranked #511 globally with a market cap of $41.73 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #90 | Thermo Fisher Scientific Inc | NYSE:TMO | $177.20 Billion | $472.71 |
| #151 | Danaher Corporation | NYSE:DHR | $122.79 Billion | $195.21 |
| #466 | IDEXX Laboratories Inc | NASDAQ:IDXX | $46.38 Billion | $586.98 |
| #511 | Lonza Group Ltd | PINK:LZAGF | $41.73 Billion | $596.13 |
VERICI DX PLC LS-001 Historical Marketcap From 2020 to 2026
Between 2020 and today, VERICI DX PLC LS-001's market cap moved from $1.04 Billion to $ 6.21 Million, with a yearly change of -59.87%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €6.21 Million | -69.23% |
| 2025 | €20.19 Million | -63.38% |
| 2024 | €55.15 Million | -65.53% |
| 2023 | €160.01 Million | -16.26% |
| 2022 | €191.08 Million | -78.04% |
| 2021 | €869.94 Million | -16.42% |
| 2020 | €1.04 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of VERICI DX PLC LS-001 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $6.21 Million USD |
| MoneyControl | $6.21 Million USD |
| MarketWatch | $6.21 Million USD |
| marketcap.company | $6.21 Million USD |
| Reuters | $6.21 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.